Ensign Peak Advisors
CTMX icon

Ensign Peak Advisors’s CytomX Therapeutics CTMX Stock Holding History

Ensign Peak Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.89M Sell
505,055
-87,418
-15% -$334K ﹤0.01% 755
2026
Q1 		$2.78M Buy
+592,473
New +$3.01M 0.01% 648

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Ensign Peak Advisors's CTMX Position: Q2 2026 in Review

Ensign Peak Advisors reduced its CytomX Therapeutics (CTMX) stake by 15% in Q2 2026, selling an estimated $334K and leaving 505,055 shares worth $1.89M. The position accounts for ﹤0.01% of the portfolio, ranked #755.

Ensign Peak Advisors first reported a position in CTMX in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.78M in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Ensign Peak Advisors held 505,055 shares of CytomX Therapeutics worth $1.89M as of Q2 2026.
  • Ensign Peak Advisors sold 87,418 CytomX Therapeutics shares in Q2 2026, an estimated $334K.
  • CytomX Therapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #755 holding.
  • Ensign Peak Advisors first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Ensign Peak Advisors's CytomX Therapeutics position peaked at $2.78M in Q1 2026.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.